Isaac See, MD1; John R. Su, MD, PhD, MPH1; Allison Lale, MD, MPH1; Emily Jane Woo, MD, MPH2; Alice Y. Guh, MD, MPH1; Tom T. Shimabukuro, MD, MPH, MBA1; Michael B. Streiff, MD3; Agam K. Rao, MD1; Allison P. Wheeler, MD, MSCI4; Suzanne F. Beavers, MD1; Anna P. Durbin, MD3; Kathryn Edwards, MD4; Elaine Miller, RN, MPH1; Theresa A. Harrington, MD, MPH&TM1; Adamma Mba-Jonas, MD, MPH2; Narayan Nair, MD2; Duong T. Nguyen, DO1; Kawsar R. Talaat, MD3; Victor C. Urrutia, MD3; Shannon C. Walker, MD4; C. Buddy Creech, MD4; Thomas A. Clark, MD, MPH1; Frank DeStefano, MD, MPH1; Karen R. Broder, MD1
doi : 10.1001/jama.2021.7517
JAMA. 2021;325(24):2448-2456
Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST with thrombocytopenia had been identified among the recipients, resulting in a temporary national pause in vaccination with this product on April 13, 2021.
Yoel Angel, MD, MBA1,2; Avishay Spitzer, MD2,3,4; Oryan Henig, MD2,5; Esther Saiag, MD, MHA2,6; Eli Sprecher, MD, PhD, MBA2,7,8; Hagit Padova, MD, MHA2,9; Ronen Ben-Ami, MD2,5
doi : 10.1001/jama.2021.7152
JAMA. 2021;325(24):2457-2465
Randomized clinical trials have provided estimates of the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 infection, but its effect on asymptomatic infections remains unclear.
Lisa H. Y. Kim, MD1; Carol Saleh, MD1; Anna Whalen-Browne, MD1; Paul M. O’Byrne, MB1; Derek K. Chu, MD, PhD1,2,3
doi : 10.1001/jama.2021.7872
JAMA. 2021;325(24):2466-2479
The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting ?2-agonists (LABAs) for moderate to severe asthma remain unclear.
Li Tang, PhD1; Diego R. Hijano, MD, MSc2; Aditya H. Gaur, MD, MBBS2; Terrence L. Geiger, MD, PhD3; Ellis J. Neufeld, MD, PhD4; James M. Hoffman, PharmD, MS5; Randall T. Hayden, MD3
doi : 10.1001/jama.2021.6564
JAMA. 2021;325(24):2500-2502
Peter C. Minneci, MD, MHSc1; Erinn M. Hade, PhD2; Gregory A. Metzger, MD1; Jacqueline M. Saito, MD3; Grace Z. Mak, MD4; Katherine J. Deans, MD, MHSc1; for the Midwest Pediatric Surgery Consortium
doi : 10.1001/jama.2021.6710
JAMA. 2021;325(24):2502-2504
Stacy Wood, PhD1; Kevin Schulman, MD2,3
doi : 10.1001/jama.2021.7707
JAMA. 2021;325(24):2435-2436
Robert L. Phillips Jr, MD, MSPH1; Linda A. McCauley, RN, PhD2; Christopher F. Koller, MA3
doi : 10.1001/jama.2021.7430
JAMA. 2021;325(24):2437-2438
Joshua M. Liao, MD, MSc1,2; Risa J. Lavizzo-Mourey, MD, MBA3; Amol S. Navathe, MD, PhD3,4
doi : 10.1001/jama.2021.8562
JAMA. 2021;325(24):2439-2440
Andrea H. Ramirez, MD, MS1,5; Kelly A. Gebo, MD, MPH2,3; Paul A. Harris, PhD4
doi : 10.1001/jama.2021.7702
JAMA. 2021;325(24):2441-2442
Lindsay Ryan, MD1
doi : 10.1001/jama.2021.9321
JAMA. 2021;325(24):2443-2444
Ruth A. Karron, MD1; Nigel S. Key, MD2; Joshua M. Sharfstein, MD3
doi : 10.1001/jama.2021.7637
JAMA. 2021;325(24):2445-2447
Laura J. Davidson, MD, MS1; Charles J. Davidson, MD1
doi : 10.1001/jama.2021.2133
JAMA. 2021;325(24):2480-2494
More than 40 million people are living with either mitral or aortic valve disease worldwide, and more than 180?000 heart valve replacement surgeries are performed each year in the US. Transcatheter valve repair has emerged as an important therapeutic option for patients who are candidates for heart valve replacement.
Maryann Mason, PhD1; Ponni Arukumar, MD2; Joe Feinglass, PhD3
doi : 10.1001/jama.2021.6700
JAMA. 2021;325(24):2495-2496
Patrick Baumgart, MD1; Thomas Garrick, MD1
doi : 10.1001/jama.2021.2320
JAMA. 2021;325(24):2497-2498
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.8428
JAMA. 2021;325(24):2421-2423
Rita Rubin, MA
doi : 10.1001/jama.2021.8201
JAMA. 2021;325(24):2424-2425
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.9339
JAMA. 2021;325(24):2428
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.8969
JAMA. 2021;325(24):2428
Anita Slomski
doi : 10.1001/jama.2021.8750
JAMA. 2021;325(24):2427
Anita Slomski
doi : 10.1001/jama.2021.9693
JAMA. 2021;325(24):2427
Anita Slomski
doi : 10.1001/jama.2021.9694
JAMA. 2021;325(24):2427
Anita Slomski
doi : 10.1001/jama.2021.9695
JAMA. 2021;325(24):2427
Anita Slomski
doi : 10.1001/jama.2021.9696
JAMA. 2021;325(24):2427
Rita Rubin, MA
doi : 10.1001/jama.2021.9727
JAMA. 2021;325(24):2426
Rita Rubin, MA
doi : 10.1001/jama.2021.9728
JAMA. 2021;325(24):2426
William C. Frankel, MD1; Tom C. Nguyen, MD2
doi : 10.1001/jama.2020.19936
JAMA. 2021;325(24):2512-2513
Raymond E. Phillips, MD1
doi : 10.1001/jama.2021.6018
JAMA. 2021;325(24):2504-2505
Jeffrey N. Katz, MD, MSc1; Kaetlyn Arant, BA1; Richard F. Loeser, MD2
doi : 10.1001/jama.2021.6024
JAMA. 2021;325(24):2505
Tomohiko Sato, MD, PhD1; Rui Terada, MD, PhD2; Toshiyuki Ikeda, MD2
doi : 10.1001/jama.2021.6033
JAMA. 2021;325(24):2505-2506
Gregory Ducrocq, MD, PhD1; Tabassome Simon, MD, PhD2; P. Gabriel Steg, MD1; for the REALITY Investigators
doi : 10.1001/jama.2021.6039
JAMA. 2021;325(24):2506-2507
doi : 10.1001/jama.2021.9012
JAMA. 2021;325(24):2507
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟